Bimagrumab
Anti-activin type II receptor antibody
Bimagrumab (Anti-activin type II receptor antibody) is a metabolic & fat loss research compound. A monoclonal antibody that blocks the activin type II receptor, preventing myostatin and activin from signalling. Blocking that pathway removes the brake on muscle growth — the result in trials is simultaneous fat loss and lean mass GAIN, which is close to unique and is exactly why it's being studied alongside GLP-1s, where muscle loss is the main criticism.
Bimagrumab quick facts
| Reported research dose | 10mg/kg every 4 weeks |
| Route | IV (trials) |
| Frequency | Monthly IV in trials |
| Half-life | Weeks (monoclonal antibody) |
| Forms | Other |
| Evidence level | Phase 2 human trials |
The most interesting thing in the body-composition space right now, and not available. It is an investigational biologic given intravenously in trials — not something in grey-market circulation, and anything sold under this name almost certainly isn't it. Watch the GLP-1 combination trials.
How Bimagrumab works
A monoclonal antibody that blocks the activin type II receptor, preventing myostatin and activin from signalling. Blocking that pathway removes the brake on muscle growth — the result in trials is simultaneous fat loss and lean mass GAIN, which is close to unique and is exactly why it's being studied alongside GLP-1s, where muscle loss is the main criticism.
Proposed benefits
Researched for fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
✅ Clinically validated
- Reached phase 2 with a genuinely unusual result. A randomised trial in obese adults with type 2 diabetes reported roughly 20% loss of fat mass alongside a ~4% gain in lean mass over 48 weeks — body recomposition, not weight loss, and the scale weight barely moved.
- It failed its earlier target indications. A phase 2b/3 in sporadic inclusion body myositis missed its primary endpoint despite increasing muscle mass — a clean example of mass without function, which is the single most important caveat about this mechanism.
📊 Correlative data
- No marketed use; it was acquired by Eli Lilly and is being studied in combination with tirzepatide, on the logic that it addresses GLP-1's lean-mass problem.
- Trial adverse effects were mostly muscle cramps, diarrhoea and acne. Long-term data does not exist.
🧪 Theoretical / extrapolated
- A monoclonal antibody blocking the activin type II receptor, which is the shared receptor for myostatin and the activins — the negative regulators of muscle mass. Block the receptor and you remove the brake.
- Blocking the receptor rather than one ligand is the design choice, and it is why the effect is larger than myostatin inhibition alone: several ligands converge there.
- The IBM failure is the mechanism's own warning. Removing a growth brake adds tissue; it does not guarantee that tissue is functional or well-innervated. And ActRII signalling does other things — the same pathway is involved in bone and reproductive biology.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
Bimagrumab — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- These slow gastric emptying and act on hypothalamic and brainstem appetite centres. Almost everything that goes wrong follows from the gastric emptying, not from anything exotic: nausea, early fullness, reflux, constipation, and — when someone titrates faster than their gut adapts — vomiting.
- The composition risk is the one nobody warns about. Appetite suppression does not discriminate. It suppresses the appetite for protein too, and in a deficit without adequate protein and a resistance stimulus a meaningful share of the loss is lean mass. That lowers the maintenance intake you eventually eat back into, which is the mechanism behind most of the rebound stories.
- Slowed emptying also delays absorption of anything else taken by mouth — a pharmacokinetic consequence rather than a drug interaction, but it matters for anything time-critical.
What has actually been reported
- GI effects are extremely common and mostly settle over weeks. Gallbladder problems are a recognised signal, and rapid weight loss of any cause raises gallstone risk — the drug is not doing something unusual, it is doing rapid weight loss well.
- Pancreatitis is reported and rare. The presentation to know is severe upper abdominal pain radiating to the back, usually with vomiting.
- A thyroid C-cell tumour signal exists in rodents and has not been demonstrated in humans; it is why the labelled contraindication for medullary thyroid carcinoma and MEN2 exists.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Follow the titration schedule even if you feel fine. It exists for gut adaptation, not for legal cover. Almost everyone who quits in the first month escalated faster than their stomach could keep up.
- Hit your protein target first at every meal, before anything else on the plate. This is the single highest-leverage habit on the drug — 1.6–2.2 g/kg, and eat it while you still have the appetite to.
- Lift while you are on it. The compound handles intake; resistance training is the only thing handling what you keep.
- Aim for 0.5–1% of bodyweight per week, deliberately. The drug removes the hunger signal that would normally stop you going too hard, so the rate has to be a decision rather than a by-product.
- Fibre and electrolytes from day one, not from week four when constipation has already made up your mind about the drug.
- If nausea is winning, step back one dose rather than quitting the class. Almost nobody needs to be at the top of the range.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- HbA1c and fasting glucose should improve — that is the drug working, and it is the cleanest confirmation you have.
- Rapid loss moves lipids, liver enzymes and uric acid transiently. A wobble at 8 weeks into aggressive loss is usually the loss, not a new problem — but it is a reason to have the baseline.
- Worth a thyroid panel and a lipid panel before starting, simply so a later result has something to be compared against.
Don't run this if
- Personal or family history of medullary thyroid carcinoma, or MEN2.
- Previous pancreatitis.
- Active gastroparesis — you would be adding a drug whose main action is the thing already wrong.
The honest unknown
- What happens to body composition over repeated multi-year cycles of loss and regain on and off these drugs. Weight is well studied; the muscle-to-fat ratio of what comes back is not.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Can you actually get Bimagrumab?
A discontinued Novartis investigational antibody. It was never approved, no pharmacy dispenses it, and no telehealth service can prescribe it. Here because the myostatin data is genuinely interesting — not because you can get it.
Bimagrumab — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What Bimagrumab moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- HbA1c (Hemoglobin A1c) — ↓ expected to fall
Falling HbA1c is the compound working. Expect it.
What to do: Baseline and 12 weeks. It moves slowly by design — a 4-week retest tells you very little. - Fasting Insulin — ↓ expected to fall
Insulin sensitivity improves as weight falls and the incretin effect restores first-phase insulin release.
What to do: Useful alongside HbA1c; the two together read the trend properly. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to fall
Triglycerides in particular fall with weight loss and improved insulin sensitivity.
What to do: Re-check at 12 weeks rather than chasing early numbers. - Lipase — ↑ expected to rise
Lipase and amylase can rise without pancreatitis on this class. An isolated mild elevation in someone with no symptoms is common.
What to do: Severe, persistent abdominal pain radiating to the back is the thing that matters, not the number. Symptoms decide, not a mild enzyme rise. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Rapid weight loss and reduced intake shift electrolytes and kidney markers; dehydration from nausea or vomiting shows up here first.
What to do: Worth a baseline. If you have been vomiting, this is the panel that catches the consequence. - Ferritin — ↓ expected to fall
Not the drug — the eating. Sharply reduced intake drops iron, B12 and protein intake with it, and this is the most commonly missed consequence of a good response.
What to do: Check ferritin and B12 at 12 weeks. Muscle loss and hair shedding on a GLP-1 is very often a nutrition problem wearing a drug's name.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for Bimagrumab — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →The pattern with this class is that the frightening-looking numbers (lipase) are usually fine and the boring ones (ferritin, B12) are where the real damage happens.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
Get the complete breakdown for Bimagrumab — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Bloodwork to run alongside Bimagrumab
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | Where you started, so you can prove the change was real |
| Fasting Insulin | Moves years before HbA1c does — the earliest signal you get |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Rapid fat loss shifts triglycerides fast, in both directions |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes while intake is restricted |
The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.
Check results you already have → · All 102 markers A–Z
Bimagrumab — frequently asked questions
What is Bimagrumab?
Bimagrumab (Anti-activin type II receptor antibody) is a metabolic & fat loss research compound. A monoclonal antibody that blocks the activin type II receptor, preventing myostatin and activin from signalling. Blocking that pathway removes the brake on muscle growth — the result in trials is simultaneous fat loss and lean mass GAIN, which is close to unique and is exactly why it's being studied alongside GLP-1s, where muscle loss is the main criticism.
Is the full Bimagrumab protocol on this page?
The reported research dose is on this page, along with how Bimagrumab works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside the Academy.
What is the half-life of Bimagrumab?
Bimagrumab has an approximate half-life of Weeks (monoclonal antibody), which is part of what determines how often it's dosed.
What's the evidence behind Bimagrumab?
Current evidence level: Phase 2 human trials. Bimagrumab is offered for research purposes only and is not an approved medicine.
Want Coach Cam's exact Bimagrumab protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What Bimagrumab is used for
Bimagrumab appears under 2 goals in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.